Clinical Development Contract Manufacturing Hormones Pharmacy 
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
Expert insights. Personalized for you.
113 
Let's personalize your content